• 1
    Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346: 75263.
  • 2
    Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 2000; 15: 14551.
  • 3
    Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295306.
  • 4
    Ames PR, Margarita A, Delgado Alves J, Tommasino C, Iannaccone L, Brancaccio V. Anticardiolipin antibody titer and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus 2002; 11: 20814.
  • 5
    Medina G, Casaos D, Jara LJ, Vera-Lastra O, Fuentes M, Barile L, et al. Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome. Ann Rheum Dis 2003; 62: 60710.
  • 6
    Courdray N, de Zuttere D, Bletry O, Piette J, Wechsler B, Godeau P, et al. M mode and Doppler echocardiographic assessment of left ventricular diastolic function in primary antiphospholipid syndrome. Br Heart J 1995; 74: 5315.
  • 7
    Hasnie AM, Stoddard MF, Gleason CB, Wagner SG, Longaker RA, Pierangeli S, et al. Diastolic dysfunction is a feature of the antiphospholipid syndrome. Am Heart J 1995; 129: 100913.
  • 8
    Nihoyannopoulos P, Gomez PM, Joshi J, Loizou S, Walport MJ, Oakley CM. Cardiac abnormalities in systemic lupus erythematosus: association with raised anticardiolipin antibodies. Circulation 1990; 82: 36975.
  • 9
    Khamashta MA, Cervera R, Asherson RA, Font J, Gil A, Coltart DJ, et al. Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet 1990; 335: 15414.
  • 10
    Roldan CA, Shively BK, Lau CC, Gurule FT, Smith EA, Crawford MH. Systemic lupus erythematosus valve disease by transesophageal echocardiography and the role of antiphospholipid antibodies. J Am Coll Cardiol 1992; 20: 112734.
  • 11
    Gabrielli F, Alcini E, Di Prima MA, Mazzacurati G, Masala C. Cardiac valve involvement in systemic lupus erythematosus and primary antiphospholipid syndrome: lack of correlation with antiphospholipid antibodies. Int J Cardiol 1995; 51: 11726.
  • 12
    Omdal R, Lunde P, Rasmussen K, Mellgren SI, Husby G. Transesophageal and transthoracic echocardiography and Doppler-examinations in systemic lupus erythematosus. Scand J Rheumatol 2001; 30: 27581.
  • 13
    Perez-Villa F, Font J, Azqueta M, Espinosa G, Pare C, Cervera R, et al. Severe valvular regurgitation and antiphospholipid antibodies in systemic lupus erythematosus: a prospective, long-term, followup study. Arthritis Rheum 2005; 53: 4607.
  • 14
    Lockshin M, Tenedios F, Petri M, McCarty G, Forastiero R, Krilis S, et al. Cardiac disease in antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus 2003; 12: 51823.
  • 15
    Leung WH, Wong KL, Lau CP, Wong CK, Liu HW. Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus. Am J Med 1990; 89: 4119.
  • 16
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 12717.
  • 17
    Petri M, Buyon J, Skovron ML, Kim M, SELENA Study Group, Belmont B, Hahn K, et al. Reliability of SELENA, SLEDAI and flare as clinical trial outcome measures [abstract]. Arthritis Rheum 1998; 41 Suppl 9: S218.
  • 18
    Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 3639.
  • 19
    Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 130911.
  • 20
    Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem 1993; 39: 176479.
  • 21
    Devereux RB, Roman MJ. Evaluation of cardiac and vascular structure and function by echocardiography and other noninvasive techniques. In: LaraghJH, BrennerBM, editors. Hypertension: pathophysiology, diagnosis, and management. Vol. 2. New York: Raven Press; 1995. p. 196985.
  • 22
    Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 107283.
  • 23
    Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al, for the American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 1989; 2: 35867.
  • 24
    Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 4508.
  • 25
    Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: echocardiographicangiographic relations in the presence or absence of asynergy. Am J Cardiol 1976; 37: 711.
  • 26
    Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003; 16: 777802.
  • 27
    Roman MJ, Pickering TG, Schwartz JE, Pini R, Devereux RB. Relation of arterial structure and function to left ventricular geometric patterns in hypertensive adults. J Am Coll Cardiol 1996; 28: 7516.
  • 28
    Pauca AL, O'Rourke MF, Kon ND. Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. Hypertension 2001; 38: 9327.
  • 29
    Hirai T, Sasayama S, Kawasaki T, Yagi S. Stiffness of systemic arteries in patients with myocardial infarction: a noninvasive method to predict severity of coronary atherosclerosis. Circulation 1989; 80: 7886.
  • 30
    Saba PS, Roman MJ, Pini R, Spitzer M, Ganau A, Devereux RB. Relation of arterial pressure waveform to left ventricular and carotid anatomy in normotensive subjects. J Am Coll Cardiol 1993; 22: 187380.
  • 31
    Simantov R, LaSala JM, Lo SK, Gharavi AE, Sammaritano LR, Salmon JE, et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995; 96: 22119.
  • 32
    Papa ND, Raschi E, Moroni G, Panzeri P, Borghi MO, Ponticelli C, et al. Anti-endothelial cell IgG fractions from systemic lupus erythematosus patients bind to human endothelial cells and induce a pro-adhesive and a pro-inflammatory phenotype in vitro. Lupus 1999; 8: 4239.
  • 33
    Cavusoglu Y, Timuralp B, Us T, Akgun Y, Kudaiberdieva G, Gorenek B, et al. Cigarette smoking increases plasma concentrations of vascular cell adhesion molecule-1 in patients with coronary artery disease. Angiology 2004; 55: 397402.
  • 34
    Wang Y, Wang L, Ai X, Zhao J, Hao X, Lu Y, et al. Nicotine could augment adhesion molecule expression in human endothelial cells through macrophages secreting TNF-α, IL-1β. Int Immunopharmacol 2004; 4: 167586.
  • 35
    Zavaleta NE, Montes RM, Soto ME, Vanzzini NA, Amigo MC. Primary antiphospholipid syndrome: a 5-year transesophageal echocardiographic followup study. J Rheumatol 2004; 31: 24027.
  • 36
    Libman E, Sacks B. A hitherto undescribed form of valvular and mural endocarditis. Arch Intern Med 1924; 33: 70137.
  • 37
    Bulkley BH, Roberts WC. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy: a study of 36 necropsy patients. Am J Med 1975; 58: 24364.
  • 38
    Straaton KV, Chatham WW, Reveille JD, Koopman WJ, Smith SH. Clinically significant valvular heart disease in systemic lupus erythematosus. Am J Med 1988; 85: 64550.
  • 39
    Roldan CA, Shively BK, Crawford MH. An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. N Engl J Med 1996; 335: 142430.
  • 40
    Hojnik M, George J, Ziporen L, Shoenfeld Y. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 1996; 93: 157987.
  • 41
    Figueroa F, Berrios X, Gutierrez M, Carrion F, Goycolea JP, Riedel I, et al. Anticardiolipin antibodies in acute rheumatic fever. J Rheumatol 1992; 19: 117580.
  • 42
    Ilarraza H, Marquez MF, Alcocer A, Banales JL, Nava AH, Reyes PA. Anticardiolipin antibodies are not associated with rheumatic heart disease. Lupus 2001; 10: 8735.
  • 43
    Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399406.
  • 44
    Hughson MD, McCarty GA, Sholer CM, Brumback RA. Thrombotic cerebral arteriopathy in patients with the antiphospholipid syndrome. Mod Pathol 1993; 6: 64453.
  • 45
    Kupferwasser LI, Hafner G, Mohr-Kahaly S, Erbel R, Meyer J, Darius H. The presence of infection-related antiphospholipid antibodies in infective endocarditis determines a major risk factor for embolic events. J Am Coll Cardiol 1999; 33: 136571.
  • 46
    Winslow TM, Ossipov MA, Fazio GP, Simonson JS, Redberg RF, Schiller NB. Five-year follow-up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus. Am Heart J 1995; 129: 5105.
  • 47
    Krause I, Lev S, Fraser A, Blank M, Lorber M, Stojanovich L, et al. Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis 2005; 64: 14903.
  • 48
    Levine SR, Salowich-Palm L, Sawaya KL, Perry M, Spencer HJ, Winkler HJ, et al. IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death: a prospective cohort study. Stroke 1997; 28: 16605.